59results about How to "Reduce nerve damage" patented technology

The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include deoxygenated hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.

The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue or red blood cells with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.

The invention discloses a quaternary ammonium salt compound as well as a preparation method and application thereof, and belongs to the field of chemical medicines. The present invention provides a compound represented by a formula I, or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a prodrug, or a metabolite thereof. The compound takes effect fast, a long-time local anesthesia effect is achieved after single administration, the sensory nerve blocking time is longer than the motor nerve blocking time, the long-acting local anesthetic effect and the selective local anesthetic effect are achieved, and meanwhile, the side effect of the quaternary ammonium salt compound with the structural characteristics of a surfactant is obviously reduced. The compound has high safety, namely, the compound shown in the formula I and the pharmaceutically acceptable salt thereof can be used for preparing safe medicines with long-time local anesthesia and selective local anesthesia effects. The compound has the advantages of long local anesthesia action time, good local anesthesia selectivity and high safety.

The invention provides methods and compositions for minimizing, preventing, or treating damage to corneal nerves by administering to a subject with such damage or at risk of exposure to such damage a composition which blocks an activity of an IL-1 cytokine and/or an IL-17 cytokine.

The invention discloses short chain polypeptide capable of promoting TFEB nuclear translocation, linear short chain polypeptide based on the short chain polypeptide, and an application of the short chain polypeptide to alleviating cerebral ischemia damage, and belongs to the technical field of biological pharmaceuticals. The short chain polypeptide disclosed by the invention is short chain polypeptide obtained through fusing function areas combined from TFEB protein and 14-3-3 protein, and the nucleotide sequence is as shown in SEQ.ID.NO.1. The invention further discloses the linear short chain polypeptide protecting the short chain polypeptide. The linear short chain polypeptide is obtained through fusing cell-penetrating peptide with the short chain polypeptide. Experiment verifies thatthe synthesized peptide can adjust and control TFEB nuclear translocation, and promote CMA to alleviate cell injury. Therefore, the invention discloses an application of the short chain polypeptide totreatment new target points for alleviating nerve cell death and improving cerebral ischemia damage.

The invention discloses short chain polypeptide capable of inhibiting the binding of MD2 and CIRP protein and application of the short chain polypeptide and belongs to the technical field of biomedicines. The short chain polypeptide disclosed by the invention is fusion peptide based on a cell-penetrating peptide TAT sequence and a CIRP protein and MD2 protein binding sequence. A nucleotide sequence is shown as SEQ ID NO. 3. An experiment proves that the synthesized fusion peptide can be used for regulating and controlling the function of MD2. Therefore, the invention discloses the applicationof the short chain polypeptide to simultaneous inhibition of inflammatory response, apoptosis and necroptosis and a new treatment target spot for promoting wound repairing.

The invention provides a memory alloy auto-distraction locking interbody fusion cage which consists of a main body, auto-distraction holes, locking teeth, holding holes and a bone grafting hole, wherein the auto-distraction holes are symmetrically formed in two sides of the main body; the locking teeth are symmetrically formed in the upper sides and the lower sides of the auto-distraction holes, and the tooth tips of the locking teeth face outwards; the holding holes are located at the rear part of the main body; the bone grafting hole of which the shape is consistent with that of the main body is formed in the center of the main body and takes the inner edge of the main body as the boundary; and the auto-distraction locking interbody fusion cage is made from medical memory alloy. When the memory alloy auto-distraction locking interbody fusion cage is used, the locking teeth are pressurized at low temperature, and after the bone grafting hole is filled with a bone grafting material, a holder is adopted to clamp the holding holes to enable the memory alloy auto-distraction locking interbody fusion cage to enter through an operative route to be placed in an objective intervertebral space; after rewarming, the auto-distraction holes restore to the shape before pressurizing, and the tooth tips of the locking teeth are inserted into upper and lower vertebral endplates of the intervertebral space to complete distraction, pressurization and locking stabilization, so that the purpose of distracting and fixing vertebral bodies of the adjacent segments of the intervertebral space is achieved, and the operation is simple.

The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.

A compound is shown in formula I and can be in the form of a pharmaceutically acceptable salt, or a stereoisomer, or a solvate, or a prodrug, or a metabolite. The compound takes effect rapidly and has a long-time local anesthetic effect following a single dose, with the sensory nerve blocking time being greater than the motor nerve blocking time, has both a long-acting local anesthetic effect and a selective local anesthetic effect, significantly reduces side effects of the compositions QX314 and QX314 and a quaternary ammonium salt compound with surfactant structural characteristics, and is safer. The compound of formula I of the present invention and a pharmaceutically acceptable salt thereof can be used for preparing drugs that have a long-time local anesthetic effect and a selective local anesthetic effect.

The invention relates to the technical field of traditional Chinese medicine formulas and preparation methods thereof, and particularly relates to a traditional Chinese medicine formula for stopping novel drug addiction and carrying out rehabilitation treatment on sequelae and a preparation method thereof. The traditional Chinese medicine formula comprises the following components in parts by weight: 20-45 parts of carambola flowers, 30-35 parts of salvia miltiorrhiza, 20-35 parts of polygala amflra, 30-45 parts of rhizoma acori graminei, 9-18 parts of gardenia jasminoides, 15-30 parts of fructus schizandrae, 25-50 parts of dried tangerine or orange peel, 40-50 parts of herba violae, 30-35 parts of radix semiaquilegiae, 40-50 parts of dandelion roots, 30-35 parts of Chinese milkwort, 20-30 parts of semen ziziphi spinosae, 20-30 parts of feather cockscomb seeds, 25-30 parts of mother-of-pearl, 30-35 parts of snakegourd seeds, 20-30 parts of pinellia ternate, and 10-20 parts of fritillaria cirrhosa. The traditional Chinese medicine formula disclosed by the invention is good in curative effect, and fills up a gap in stopping domestic novel drug addiction and carrying out rehabilitation treatment on sequelae.

The present invention provides a method of treating stroke or reducing nerve injury comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I)

or formula (II)

wherein W represents

R1 represents

R2 represents

R3 represents

R4 represents

and R represent H or alkyl groups of C1-C6.

The invention relates to the use of at least on inhibitor selected from the group consisting of raf-, protein kinase C(PKC)-, MEK1/2-, or ERK1/2-inhibitors, for the manufacturing of a medicament to be administrated from 1 up to 12 hours after initiation of an ischemic disease.

The invention discloses a special puncture needle for ultrasonic guidance of great auricular nerve block. The special puncture needle comprises a puncture portion, a connecting portion and a needle seat, wherein a sharp end portion is arranged at one end of the puncture portion; the other end of the puncture portion is fixedly connected to the connecting portion; the other end of the connecting portion is fixedly connected to the needle seat; and an axial line of the puncture portion forms a 120-degree included angle with an axial line of the connecting portion. The special puncture needle for the ultrasonic guidance of the great auricular nerve block provided by the invention can better meet the clinical demand of the great auricular nerve block and optimize clinical operations, so as to facilitate clinical anesthetists to efficiently and conveniently implement the ultrasonic guidance of the great auricular nerve block; and meanwhile, puncture trauma and pain can be reduced, and the occurrence rate of such complications as nerve injury, local hematoma and the like can be reduced.

The present invention provides a method for treating or reducing damage to the optic nerve in a subject comprising administering to the subject a therapeutically effective amount of prostaglandin J2 alone or in combination with an effective amount of GM-CSF. In particular aspects of the invention, the subject is a mammal, and in further aspects the mammal is a human.

The disclosure provides compositions and methods for treating or preventing intracerebral hemorrhage (ICH) in a subject by administering a variant of FXa.

The invention discloses application of baohuoside I in preparation of a drug for preventing and treating cerebral arterial thrombosis. The baohuoside I is adopted to prepare a drug for preventing and treating cerebral arterial thrombosis. The prepared pharmaceutical composition has a protective role on acute cerebral arterial thrombosis by verification of a series of animal experiments, and the measurement is associated with the baohuoside I for stopping reduction of PPARalpha and PPARgamma expression, and inhibiting of activation of an IkB/NF-kB channel, so as to inhibit overexpression of inflammatory factors such as 1L-1beta, TGFbeta1 and the like.

The invention relates to an improved device for percutaneous tracheotomy. The device comprises an outer sleeve, a puncture needle and a guide wire. The outer sleeve is made of stainless steel materials, the whole outer sleeve is in a linear shape, outer sleeve scale marks are arranged on the outer wall of the outer sleeve, the head end of the outer sleeve is designed to be of a spoon-shaped inclined face, an outer sleeve connecting base is arranged at the tail end of the outer sleeve, and a first identification component is arranged on the outer sleeve connecting base; the position of the first identification part on the outer sleeve connecting base is used for indicating the direction of a guide wire guided by the spoon-shaped inclined surface at the head end of the outer sleeve; a puncture needle connecting base is arranged at the tail end of the puncture needle, a second identification component is arranged on the outer wall of the puncture needle connecting base, and the second identification component is matched with the first identification component; and guide wire scale marks are arranged on the outer wall of the guide wire. The device can realize accurate, safe and convenient implementation of percutaneous tracheotomy.